Oral RORy nuclear receptor antagonist
on-going Ph. II for psoriasis (QD dosing)
50k cmpd high-conc. frag. screen + scaff. hop
ACS Med. Chem. Lett., Jan. 5, 2021
Boehringer Ingelheim, Ridgefield, CT
The Boehringer RORγ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for plaque psoriasis. We highlighted two other RORγ modulators last year in February and March. While most clinical RORγ modulators have discontinued development after reaching Ph. II, BI 730357’s Ph. II trial appears to be on-going.